Coherus BioSciences, Inc. (CHRS) EPS Estimated At $-0.84 as of May, 14

April 17, 2018 - By Nellie Rakes

Coherus BioSciences, Inc. (NASDAQ:CHRS) Corporate Logo
During 2017 Q4 the big money sentiment increased to 1.16. That’s change of 0.09, from 2017Q3’s 1.07. 13 investors sold all, 24 reduced holdings as Coherus BioSciences, Inc. ratio is positive. 32 increased holdings while 11 funds took holdings. Funds hold 49.09 million shares thus 5.36% more from 2017Q3’s 46.59 million shares.
First Personal Finance Ser has 1,476 shs for 0% of their capital. Guggenheim holds 0% or 16,248 shs. Tiaa Cref Investment Mngmt Ltd Liability has invested 0.01% in Coherus BioSciences, Inc. (NASDAQ:CHRS). D E Shaw holds 0% of its capital in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 38,106 shs. Brown Advisory has 0.02% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 633,035 shs. Millennium Mngmt Lc holds 0.01% of its capital in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 695,286 shs. Schwab Charles Investment Mgmt invested in 189,697 shs. Alyeska Inv Gru L P holds 0.04% or 484,581 shs in its capital. Legal And General Pcl reported 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS). Parametric Portfolio Assoc Limited Liability Corporation holds 0% or 19,950 shs in its capital. Northern Corporation holds 0% of its capital in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 468,540 shs. Price T Rowe Associate Md holds 0% of its capital in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 919,202 shs. Cornerstone Cap Management Holding Lc has 0% invested in Coherus BioSciences, Inc. (NASDAQ:CHRS) for 35,762 shs. Rock Springs Capital Mngmt Ltd Partnership owns 629,500 shs or 0.25% of their US capital. Td Asset stated it has 0% in Coherus BioSciences, Inc. (NASDAQ:CHRS).

Coherus BioSciences, Inc. (NASDAQ:CHRS)’s quarterly earnings will be announced On May, 14., according to Faxor. EPS of $-0.84 is 45.45 % up from 2017’s $-1.54 EPS. After $-0.84 EPS was announced last quarter, analysts now see EPS growth of 0.00 % for Coherus BioSciences, Inc.. The stock decreased 1.37% or $0.18 during the last trading session, reaching $12.57.Coherus BioSciences, Inc. has volume of 64,964 shares. Since April 17, 2017 CHRS has declined 49.07% and is downtrending. The stock underperformed the S&P 500 by 60.62%.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Ratings Coverage

In total 2 analysts cover Coherus Biosciences (NASDAQ:CHRS). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 3 are the (NASDAQ:CHRS)’s analyst reports since November 7, 2017 according to StockzIntelligence Inc. The stock rating was maintained by Maxim Group with “Buy” on Friday, March 9. In Friday, March 9 report Citigroup maintained the stock with “Buy” rating.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide.The firm is worth $756.44 million. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma.Currently it has negative earnings. The Company’s product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

Coherus BioSciences, Inc. (NASDAQ:CHRS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: